Tom3 schreef op 2 juli 2021 10:28:
Ik zie nog steeds niet waarom het concept van Affimed inferieur zou moeten zijn aan dat van Fate als ze het combineren met donor NK cellen. De hoofdprijs is natuurlijk AFM24 en daar komt ook voorzichtig enige tekening in getuige de conference call van gisteren waar Hoess kennelijk nog steeds lichtpuntjes ziet:
"As announced today, we have now completed dose cohort 5 at 320 milligram and recruitment of patients into cohort 6 has begun at a dose level of 480 milligrams, which is a 50% increase in dose from cohort 1. The decision to increase to 480 milligram was driven by data derived from the cohort 1 to 5. Specifically, our decision was informed by pharmacodynamic data from cohort 1 to 4 and pharmacokinetic data from cohort 1 to 5. Key and indeed very encouraging findings are that we are seeing a more than dose-proportional increase in exposure as we escalate the dose, and the increase in exposure is now correlated with increases in activation markers on natural killer cells and CD16A receptor occupancy.Importantly, we have not observed times of NK cell exhaustion
. In terms of safety, no medical relevant drug-related targets has been reported other than infusion-related reaction, which are managed to stand the pre-medication. We have indeed not seen any of the classical EGFR-related toxicity to cohort 5, such as skin or other organ toxicity. Subject to additional dosing steps, we plan to determine the recommended Phase II dose, and we are expecting to begin the expansion cohorts in the second half of this year."
De EGFR markt is oneindig veel interessanter dan de BCMA markt (waarvoor Fate inmiddels alleen al twee kandidaten heeft).